[{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Agreement","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Exeltis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Lupin Ltd"},{"orgOrder":0,"company":"Exeltis","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Rizatriptan Benzoate","moa":"Serotonin 1d (5-HT1d) receptor | Serotonin 1b (5-HT1b) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Film","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Luye Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Rivastigmine","moa":"Cholinesterases; ACHE & BCHE","graph1":"Neurology","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exeltis \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Exeltis \/ Exeltis"},{"orgOrder":0,"company":"Exeltis","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenticonazole Nitrate","moa":"sterol","graph1":"Undisclosed","graph2":"Phase I","graph3":"Exeltis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exeltis \/ Monitor CRO","highestDevelopmentStatusID":"6","companyTruncated":"Exeltis \/ Monitor CRO"}]

Find Clinical Drug Pipeline Developments & Deals by Exeltis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 04, 2022

                          Lead Product(s) : Fenticonazole Nitrate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Monitor CRO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Through the agreement, the company grants Exeltis exclusive rights to commercialize the Rivastigmine MD (rivastigmine), a multi-day transdermal patch for the treatment of Alzheimer’s disease.

                          Product Name : Rivalif

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Rivastigmine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Luye Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.

                          Product Name : Solosec

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          January 27, 2022

                          Lead Product(s) : Secnidazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Under the terms of the current agreement, IntelGenx will grant Exeltis an exclusive license to manufacture and commercialize RIZAPORT® in the EU.

                          Product Name : Rizaport

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 27, 2020

                          Lead Product(s) : Rizatriptan Benzoate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : IntelGenx

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Under the agreements, Exeltis Healthcare will commercialize NaMuscla® in Spain and Portugal, Cresco Pharma B.V will commercialize NaMuscla® in the Netherlands and Macure Pharma ApS in the Nordic countries. Lupin will continue commercialization of NaMus...

                          Product Name : NaMuscla

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 06, 2020

                          Lead Product(s) : Mexiletine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : Lupin Ltd

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 18, 2019

                          Lead Product(s) : INM004

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Exeltis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 15, 2019

                          Lead Product(s) : Tioconazole

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Monitor CRO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          November 14, 2018

                          Lead Product(s) : 14-C Benznidazole

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Insud Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank